Why is Ocugen (OCGN) stock soaring? Here's what you must know

February 23, 2022 07:21 PM AEDT | By Raza Naqvi
 Why is Ocugen (OCGN) stock soaring? Here's what you must know
Image source: © Pichitbo | Megapixl.com
Highlights:
  • On February 22, Ocugen announced the pricing of its underwritten public offering.
  • Dr Shankar Musunuri, chief executive officer and co-founder of Ocugen said that the company can now move COVAXIN™'s clinical program forward.
  • Ocugen is expected to continue the phase 3 study for securing Emergency Use Authorization (EUA) of the vaccine in the United States.

Stocks of Ocugen, Inc. (NASDAQ:OCGN) surged 22.3 per cent on Tuesday, February 22, as investors responded positively to a significant development announced by the company on Friday, February 18.

As markets remained closed on Monday due to President's Day celebrations, the surge in the share prices came at the start of the trading session.

On Friday, the Food and Drug Administration (FDA) lifted the clinical hold on Ocugen's Investigational New Drug (IND) application.

Also Read: What is PayMongo and why is it grabbing attention?

The application was filed to evaluate the COVID-19 vaccine candidate called BBV152. Notably, the BBV152 vaccine is called COVAXIN™ outside of the United States.

In November last year, the FDA had placed a clinical hold on the IND application, which restricted Ocugen from starting its planned phase 3 study of the vaccine candidate.

What's next for Ocugen (NASDAQ:OCGN)

Dr Shankar Musunuri, chief executive officer and co-founder of Ocugen, said that the company can now move COVAXIN™'s clinical program forward.

Bharat Biotech developed COVAXIN™ through collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

Ocugen (OCGN) stock                                                                                                   ©2022 Kalkine Media® 

Outside of the United States, more than 200 million doses of COVAXIN™ have been administered and 20 countries have authorized the vaccine for emergency use.

Ocugen is expected to continue the phase 3 study for securing Emergency Use Authorization (EUA) of the vaccine in the United States. Notably, the World Health Organization (WHO) also added COVAXIN™ in the list of vaccines for emergency use.

Bottom line

On February 22, Ocugen announced the pricing of a public offering. The company is set to offer 15,973,420 million shares of common stock for around US$ 53.5 million.

The underwritten public offering is expected to close on February 25, and the underwriter would have an option of purchasing 2.4 million additional shares within 30 days.

As per the company statement, Cantor Fitzgerald & Co. was given the underwriting responsibility for the proposed offering.

Also Read: Can you buy TRUTH Social stock?

Ocugen is offering the common stock pursuant to a registration statement filed the Securities and Exchange Commission. The company had previously filed Form S-3ASR on March 22 last year.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.